Tiotropium in COPD patients not previously receiving maintenance respiratory medications

Sandra G Adams, Antonio R Anzueto, Dick D. Briggs, Shailendra S. Menjoge, Steven Kesten

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: Use of maintenance bronchodilator therapy is currently recommended in symptomatic patients with Chronic obstructive pulmonary disease (COPD) and in those with Stage II or greater COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Because no prospective data describe when rescue therapy alone is insufficient or the optimal time to start maintenance therapy, it is unclear whether maintenance therapy has benefits in milder disease. To explore potential benefits we asked: Does once-daily tiotropium improve lung function, health status, and/or symptoms in "undertreated" COPD patients (i.e., those who are not receiving maintenance bronchodilator therapy) or patients considered by their health care providers as having milder disease? Methods: A post-hoc analysis of data from COPD patients participating in two, 1-year, placebo-controlled trials with tiotropium was performed. Patients were defined as "undertreated" if they received no respiratory medication or only as-needed short-acting β-agonists prior to enrollment. Measures included serial spirometry, Transition Dyspnea Index (TDI), and St. George's Respiratory Questionnaire (SGRQ). Results: Of 921 patients enrolled, 218 (23.7%) were "undertreated": 130 received tiotropium; 88 received placebo. Demographics for the two treatment groups were comparable. Tiotropium-treated patients had significantly improved forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) compared with patients using placebo on all study days. Additionally, TDI and SGRQ scores significantly improved with tiotropium compared with placebo. Conclusions: Once-daily tiotropium provides significant improvement in lung function, health status, and dyspnea when used as maintenance therapy in undertreated COPD patients who were not previously receiving maintenance bronchodilator therapy.

Original languageEnglish (US)
Pages (from-to)1495-1503
Number of pages9
JournalRespiratory Medicine
Volume100
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Chronic Obstructive Pulmonary Disease
Maintenance
Bronchodilator Agents
Placebos
Dyspnea
Therapeutics
Health Status
Tiotropium Bromide
Lung
Spirometry
Vital Capacity
Forced Expiratory Volume
Health Personnel
Demography

Keywords

  • Chronic obstructive pulmonary disease
  • Dyspnea
  • Forced expiratory volume in 1 s
  • Lung function
  • Quality of life
  • Tiotropium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Tiotropium in COPD patients not previously receiving maintenance respiratory medications. / Adams, Sandra G; Anzueto, Antonio R; Briggs, Dick D.; Menjoge, Shailendra S.; Kesten, Steven.

In: Respiratory Medicine, Vol. 100, No. 9, 09.2006, p. 1495-1503.

Research output: Contribution to journalArticle

Adams, Sandra G ; Anzueto, Antonio R ; Briggs, Dick D. ; Menjoge, Shailendra S. ; Kesten, Steven. / Tiotropium in COPD patients not previously receiving maintenance respiratory medications. In: Respiratory Medicine. 2006 ; Vol. 100, No. 9. pp. 1495-1503.
@article{5b89a0690f764215a5f37d31841bd208,
title = "Tiotropium in COPD patients not previously receiving maintenance respiratory medications",
abstract = "Introduction: Use of maintenance bronchodilator therapy is currently recommended in symptomatic patients with Chronic obstructive pulmonary disease (COPD) and in those with Stage II or greater COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Because no prospective data describe when rescue therapy alone is insufficient or the optimal time to start maintenance therapy, it is unclear whether maintenance therapy has benefits in milder disease. To explore potential benefits we asked: Does once-daily tiotropium improve lung function, health status, and/or symptoms in {"}undertreated{"} COPD patients (i.e., those who are not receiving maintenance bronchodilator therapy) or patients considered by their health care providers as having milder disease? Methods: A post-hoc analysis of data from COPD patients participating in two, 1-year, placebo-controlled trials with tiotropium was performed. Patients were defined as {"}undertreated{"} if they received no respiratory medication or only as-needed short-acting β-agonists prior to enrollment. Measures included serial spirometry, Transition Dyspnea Index (TDI), and St. George's Respiratory Questionnaire (SGRQ). Results: Of 921 patients enrolled, 218 (23.7{\%}) were {"}undertreated{"}: 130 received tiotropium; 88 received placebo. Demographics for the two treatment groups were comparable. Tiotropium-treated patients had significantly improved forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) compared with patients using placebo on all study days. Additionally, TDI and SGRQ scores significantly improved with tiotropium compared with placebo. Conclusions: Once-daily tiotropium provides significant improvement in lung function, health status, and dyspnea when used as maintenance therapy in undertreated COPD patients who were not previously receiving maintenance bronchodilator therapy.",
keywords = "Chronic obstructive pulmonary disease, Dyspnea, Forced expiratory volume in 1 s, Lung function, Quality of life, Tiotropium",
author = "Adams, {Sandra G} and Anzueto, {Antonio R} and Briggs, {Dick D.} and Menjoge, {Shailendra S.} and Steven Kesten",
year = "2006",
month = "9",
doi = "10.1016/j.rmed.2006.03.034",
language = "English (US)",
volume = "100",
pages = "1495--1503",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "9",

}

TY - JOUR

T1 - Tiotropium in COPD patients not previously receiving maintenance respiratory medications

AU - Adams, Sandra G

AU - Anzueto, Antonio R

AU - Briggs, Dick D.

AU - Menjoge, Shailendra S.

AU - Kesten, Steven

PY - 2006/9

Y1 - 2006/9

N2 - Introduction: Use of maintenance bronchodilator therapy is currently recommended in symptomatic patients with Chronic obstructive pulmonary disease (COPD) and in those with Stage II or greater COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Because no prospective data describe when rescue therapy alone is insufficient or the optimal time to start maintenance therapy, it is unclear whether maintenance therapy has benefits in milder disease. To explore potential benefits we asked: Does once-daily tiotropium improve lung function, health status, and/or symptoms in "undertreated" COPD patients (i.e., those who are not receiving maintenance bronchodilator therapy) or patients considered by their health care providers as having milder disease? Methods: A post-hoc analysis of data from COPD patients participating in two, 1-year, placebo-controlled trials with tiotropium was performed. Patients were defined as "undertreated" if they received no respiratory medication or only as-needed short-acting β-agonists prior to enrollment. Measures included serial spirometry, Transition Dyspnea Index (TDI), and St. George's Respiratory Questionnaire (SGRQ). Results: Of 921 patients enrolled, 218 (23.7%) were "undertreated": 130 received tiotropium; 88 received placebo. Demographics for the two treatment groups were comparable. Tiotropium-treated patients had significantly improved forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) compared with patients using placebo on all study days. Additionally, TDI and SGRQ scores significantly improved with tiotropium compared with placebo. Conclusions: Once-daily tiotropium provides significant improvement in lung function, health status, and dyspnea when used as maintenance therapy in undertreated COPD patients who were not previously receiving maintenance bronchodilator therapy.

AB - Introduction: Use of maintenance bronchodilator therapy is currently recommended in symptomatic patients with Chronic obstructive pulmonary disease (COPD) and in those with Stage II or greater COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Because no prospective data describe when rescue therapy alone is insufficient or the optimal time to start maintenance therapy, it is unclear whether maintenance therapy has benefits in milder disease. To explore potential benefits we asked: Does once-daily tiotropium improve lung function, health status, and/or symptoms in "undertreated" COPD patients (i.e., those who are not receiving maintenance bronchodilator therapy) or patients considered by their health care providers as having milder disease? Methods: A post-hoc analysis of data from COPD patients participating in two, 1-year, placebo-controlled trials with tiotropium was performed. Patients were defined as "undertreated" if they received no respiratory medication or only as-needed short-acting β-agonists prior to enrollment. Measures included serial spirometry, Transition Dyspnea Index (TDI), and St. George's Respiratory Questionnaire (SGRQ). Results: Of 921 patients enrolled, 218 (23.7%) were "undertreated": 130 received tiotropium; 88 received placebo. Demographics for the two treatment groups were comparable. Tiotropium-treated patients had significantly improved forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) compared with patients using placebo on all study days. Additionally, TDI and SGRQ scores significantly improved with tiotropium compared with placebo. Conclusions: Once-daily tiotropium provides significant improvement in lung function, health status, and dyspnea when used as maintenance therapy in undertreated COPD patients who were not previously receiving maintenance bronchodilator therapy.

KW - Chronic obstructive pulmonary disease

KW - Dyspnea

KW - Forced expiratory volume in 1 s

KW - Lung function

KW - Quality of life

KW - Tiotropium

UR - http://www.scopus.com/inward/record.url?scp=33746804545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746804545&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2006.03.034

DO - 10.1016/j.rmed.2006.03.034

M3 - Article

C2 - 16698259

AN - SCOPUS:33746804545

VL - 100

SP - 1495

EP - 1503

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 9

ER -